Sector News

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

November 19, 2022
Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

The facility is over 125 acres in size and received US Food and Drug Administration (FDA) approval in 2019, European Medicines Authority (EMA) site approval the following year and is now in commercial manufacture.

Employing over 450 people on campus, Cruiserath has the manufacturing capacity necessary to meet a growing demand for existing biologics products, as well as anticipated requirements for products currently within the Bristol Myers Squibb pipeline.

It also includes a cell culture suite, quality control laboratories and technology labs as well a cryogenics logistics facility. All the venture will support ongoing commercial testing, development, and manufacturing.

Padraig Keane explained: “It is a proud day at Cruiserath Biologics as we celebrate the opening of our site with the presence of our global leadership team. Biologics manufacturing is a highly complex, sensitive process, truly unique – from manufacture, to package, storage, and transit to reach our patients.”

“This requires a commitment from each employee, across every department as well as collaboration across our network. Our people are truly committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases,” he added.

Karin Shanahan, who leads the company’s global manufacturing network, commented: “The Cruiserath Biologics site will play a crucial role in our company’s success moving forward. Coupled with the breadth of knowledge and expertise of our employees, this multi-product site will allow us to further enhance our operations as we strive to get more medicines to more patients faster.”

Having opened its doors with a pharmaceutical ingredient plant in County Dublin during 1964, Bristol Myers Squibb became one of the first pharmaceutical companies in Ireland.

by John Pinching

Source: pharmatimes.com

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.